Compare Moderna, Inc. (MRNA) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Western Alliance Bancorporation — how do they compare? Moderna, Inc. trades at $214.64 (market cap $78.65B), while Western Alliance Bancorporation trades at $74.41 (market cap $8.24B). The key difference: Moderna, Inc. is far larger — about 9.5× Western Alliance Bancorporation's market cap, and Western Alliance Bancorporation pays a 2.23% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Western Alliance Bancorporation for 3 Days on average.
| MRNA | WAL | |
|---|---|---|
Market Cap | $78.65B | $8.24B |
Volume | 37,373,437 | 1,387,161 |
Sector | Health | Financials |
52-Week High | $203.46 | $96.08 |
52-Week Low | $22.36 | $66.70 |
Typical Hold Time | 59 Days | 3 Days |
Enterprise Value | $74.80B | $9.76B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
Western Alliance Bancorporation (WAL) trades at $74.22, down 0.17% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 8.52 and net income margin of 25.43%, while recent earnings have mostly beaten expectations. The company launched WA VenueX, an institutional financial platform, signaling innovation in digital banking services. Analyst consensus is strongly bullish with a $84.33 price target, though technical indicators suggest near-term caution.
WAL presents a compelling value opportunity with attractive valuation multiples and solid profitability, but faces headwinds from bearish technical trends and interest rate sensitivity. The stock's upside hinges on continued earnings growth and successful execution of new initiatives like WA VenueX, while regulatory changes and economic conditions remain key risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
